Antibody evasion by the P.1 strain of SARS-CoV-2

Antibody evasion by the P.1 strain of SARS-CoV-2

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7...

書誌詳細
主要な著者:	Dejnirattisai, W, Zhou, D, Supasa, P, Liu, C, Mentzer, AJ, Ginn, HM, Zhao, Y, Duyvesteyn, HME, Tuekprakhon, A, Nutalai, R, Wang, B, López-Camacho, C, Slon-Campos, J, Walter, TS, Skelly, D, Costa Clemens, SA, Naveca, FG, Nascimento, V, Nascimento, F, Fernandes da Costa, C, Resende, PC, Pauvolid-Correa, A, Siqueira, MM, Dold, C, Levin, R, Dong, T, Pollard, AJ, Knight, JC, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, SC, Carroll, MW, Klenerman, P, Barnes, E, Dunachie, SJ, Paterson, NG, Williams, MA, Hall, DR, Hulswit, RJG, Bowden, TA, Fry, EE, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR
フォーマット:	Journal article
言語:	English
出版事項:	Cell Press 2021

類似資料

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
著者:: Zhou, D, 等
出版事項: (2021)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
著者:: Liu, C, 等
出版事項: (2021)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
著者:: Supasa, P, 等
出版事項: (2021)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
著者:: Nutalai, R, 等
出版事項: (2022)

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
著者:: Liu, C, 等
出版事項: (2021)

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
著者:: Dejnirattisai, W, 等
出版事項: (2022)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
著者:: Tuekprakhon, A, 等
出版事項: (2022)

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
著者:: Huo, J, 等
出版事項: (2022)

Integrative structural biology of viruses
著者:: Duyvesteyn, HME
出版事項: (2019)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
著者:: Dejnirattisai, W, 等
出版事項: (2021)

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
著者:: Daming Zhou, 等
出版事項: (2024-03-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
著者:: Aiste Dijokaite-Guraliuc, 等
出版事項: (2022-11-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
著者:: Flaxman, A, 等
出版事項: (2021)

The alteration of NK cells phenotypes related to the functions and dengue disease outcomes
著者:: Napas Taechasan, 等
出版事項: (2024-07-01)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
著者:: Watanabe, Y, 等
出版事項: (2021)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
著者:: Ragonnet-Cronin, M, 等
出版事項: (2023)

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
著者:: McNaughton, AL, 等
出版事項: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
著者:: Marchevsky, NG, 等
出版事項: (2022)

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
著者:: Peng, Y, 等
出版事項: (2020)

Native-like SARS-CoV‑2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
著者:: Yasunori Watanabe, 等
出版事項: (2021-04-01)

Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
著者:: Renner, M, 等
出版事項: (2018)

Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
著者:: Fernandez, E, 等
出版事項: (2017)

The antigenic anatomy of SARS-CoV-2 receptor binding domain
著者:: Dejnirattisai, W, 等
出版事項: (2021)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
著者:: Jiandong Huo, 等
出版事項: (2022-11-01)

Evolution of neurovirulent Zika virus
著者:: Screaton, G, 等
出版事項: (2017)

Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine
著者:: Screaton, G, 等
出版事項: (2018)

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
著者:: Townsend, A, 等
出版事項: (2021)

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
著者:: Sharpe, HR, 等
出版事項: (2020)

Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen
著者:: Sheerin, D, 等
出版事項: (2021)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
著者:: Manon Ragonnet-Cronin, 等
出版事項: (2023-06-01)

Accelerating drug target inhibitor discovery with a deep generative foundation model
著者:: Chenthamarakshan, V, 等
出版事項: (2023)

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
著者:: Faria, NR, 等
出版事項: (2021)

Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.
著者:: Midgley, C, 等
出版事項: (2012)

Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells.
著者:: Elodie Décembre, 等
出版事項: (2014-10-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
著者:: Folegatti, PM, 等
出版事項: (2020)

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
著者:: Chang Liu, 等
出版事項: (2024-04-01)

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope
著者:: Alexander Rouvinski, 等
出版事項: (2017-05-01)

Humidity control as a strategy for lattice optimization applied to crystals of HLA-A*1101 complexed with variant peptides from dengue virus.
著者:: Chotiyarnwong, P, 等
出版事項: (2007)

Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine
著者:: Tsai, W, 等
出版事項: (2018)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
著者:: Voysey, M, 等
出版事項: (2023)